- Earnings call transcript Q3 2022

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good morning, ladies and gentlemen, and welcome to Aspira Women’s Health Incorporated Third Quarter 2022 Conference Call. My name is David, and I will be your coordinator for the call today. At this time, all participants are in a listen-only mode.

Following management’s prepared remarks, we will open the call for your questions.

As a reminder, this call is being recorded today. are Chief President Financial today Officer; Chief call Beechey, Bob Officer; the Nicole and Sandford, Executive Leading and Dr. Scientific Chief Phan, Officer Operating Chief Ryan Officer. and After call open the we Q&A. the prepared remarks, for will

would we under business Aspira’s will expected relating defined Securities be like Before during Private or and I to everyone future call, statements the of that Act Reform future to this future prospects remind events Litigation made performance, as forward-looking XXXX plans. statements begin, including

and the those cause Executive to actual President of recent SEC this factors that Officer. set could the ma’am. differ factors Aspira’s filed supplement in new on anticipated the reflected materially results beyond a Health as many XX-Q expectations forward-looking Aspira the in any well Please Participants future assumes risks information, that ahead, description set to a Form believes forward-looking forth control. company of statements, Women’s assumptions, I’d no press the most to today’s cautionary to directed Chief results materially to and the based the are whether outcomes Form turn and differ law. or release required Sandford, over Nicole forth from Report and result by reasonable due company as are such as like Quarterly otherwise, update are risk upon on in with go those except could XX-K Although, time, statements Report to anticipated of factors The At from forward-looking statements. the call note impact uncertainties actual for events Annual and or obligation as to subject in

Nicole Sandford

and joining you, thank us Thank today. for operator, you, everyone,

update very on are our third the progress provide quarter. an in to We pleased

call Bob initiatives provide update on and with of Chief Chief on our an key are strategic provide the who the our our to third I our Joining Officer; we Operating Ryan will product pipeline dimensions, quarter, Ryan a financial progress Dr. In growth, make session. our we and will strategic before will After Chief our excellence. handing the sustained today begin prepared development continued three an critically an Beechey, update. Financial update to with remarks, question-and-answer Scientific Phan, then third open line quarter performance. our and the Officer. call Bob, me on and for will a overview innovation important operational follow across

launch me on OvaWatch, efforts quarter. this an start confirming OvaWatch update innovation our in we that and with will Let today

fully several The of and code the Axia PLA go, November and is sales of CPT in signed submission including we Gynecology Chicago. Dr. the adopters, on unique Reilly applied Advisory of Committee Women’s Institute to for team ready and physicians a Gerard We have Dr. OvaWatch October, Nicole on Health, trained become Our and well for to respected early Williams reviewed X.

launch and New study York the we patients. New that will the our XXXX. this We this will in for validation. We approval which clinical York of to validation effective final or the stages manuscript payer publication adoption provider be laboratory notified requests, and to be and our processes are submitted been Kits waiting for X, related an approval have post-launch. study week. of are test regarding on April drive additional The and complete expect of to be We XXXX for by would completed OvaWatch tested state peer-review ready end believe to distribution

will offerings adnexal our broader to In physician decisions. experience their excited women, known clinical or of masses. positive their applicability and with OvaSuite. been and recognition have tests on provide chosen potential management confidence of the have be OvaWatch Healthcare access non-invasive will medical suite women We blood by receiving now providers of for population portfolio medicine to as practice change a feedback ovarian cancer with are a now together to of of unprecedented that the the

a OVERA women that provide time potentially pelvic or perform significant in mass meaningfully The population potential tool not. a beyond number first assess ordering healthcare also OvaSuite of OvaX the on oncologist, launch phase. that preventative identify whether gynecologist effectively to premature will our have now FDA-cleared provider will We who a opportunity unnecessary OvaX the an For patient of are This of surgery believe beyond is lifesaving female users who physician their the provide have to decided initial the and removal ever providers risk and information, primary OVERA patient expansion undergo has a and OvaWatch test. or an be opportunity the expand of of assessment. physicians that reduced, basis gynecological their to ovaries may malignancy an of and population are

women’s Following of practitioners. and family the health broadly other our be products launch more OvaWatch, to marketed OvaSuite will

said, medicine Care that clearly momentum published there refreshed in was strategy. available marketing an effective have Policy as Family Journal. OvaX and article of X, entitled Review to The the considerations family some ovarian updated and Mass, malignancy physicians In and With all youth, tool risk. and the identifies fact, On already cancer we by assessing for direction. our was that for family Primary physician Adnexal Practice July Management article a the Medicine

a our where spending more population. conferences, will can to to OvaSuite marketing we We high presentations impact of larger key physician launch shift at

have on This of launch Advisory implement our our Physician approaches of the in was developed just a our in is to marketing the programs pre-launch practices expect OvaWatch best of and We end Board as part snapshot year, that successful new field for physician which to strategy, plan territory. activities. the worked before formally most the based

we gross of operational timing now liquidity the of was capital excellence. million to small public this September, offering The Let’s our offering closed turn Starting and position. $X proceeds. In of with opportunistic.

of negotiate sustain plan. of to growth to attract the adequate I with along of provider with containment cost our ability million, cancer potential our critically year, EndoCheck. an company is commercial cash development impact the to important has provide and strategic and ovarian adoption on believe execution an this of or implementation the including which $X.X net efforts of commercial the suite and partners, Our of drive of to aggressive position will our OvaWatch part payer proceeds assessments, our our risk the campaign the launch of aggressive launch marketing strategy, and liquidity a development

capital our We and clear to have of runway we our I’m a we achieve have view the that confident initiatives. key need strategy,

and a top progress operational cash, of excellence, Moving priority. has utilization to our cash in usage innovation of been growth key managing of our another without aspect sacrificing

and quarter Farber Our in an this Cancer $X.X including for of endometriosis to was the payment cash million, $XXX,XXX testing payments. utilization portfolio Harvard’s our Institute severance $XXX,XXX Dana development

quarter. organization, moved we right we the for have a needs through our guidance. track the roles business of the on second people that half the year, then, cash organization, eliminating which reorganization we Throughout in the with was the time. look commercial with in at guidance and taking of focused very utilization of our our $XX team, reflect capacity. remain XXXX in on the Since in this We of $XX.X and first announced efforts excess that rest redundancy point Our started a and million ensuring the to we we have million, at close

are March being All of We X, when XX% taken year going believe related have our right things have $X other the we in will the will and team benefits million largely end finished that actions the since I and XXXX. the actions, headcount, into reduced payroll by became of related plus XXXX. expenses CEO. we in save payroll, I over cost with equal, the headcount this approximately of have we

for continue roles. we meet critical As hire and our key business to grows, we milestones, will

building are transparency and of when accountability culture, level a performance We every at the stresses organization. that

their the is sure goal person role in every our make understands in it. Our company and achieving to strategy

takes proud have have time, the of to this decisions despite are year. made we While retention, and this process difficult performance, work improve we employee staffing development the we done

to progress growth. our Turning and

a of same increase performed. achieved in with period XX% we quarter, XXXX. the volume over in million This a tests This $X.X X,XXX represents revenue,

As the year quarter companies the the over second diagnostic growth of from demonstrated with this to to volume quarter see as has volume well. X% Product was third second tend other the in sector, XXXX. increased been that case tapering we the

XXXX increased testing volume performed to second the to XX of Our in performed year. day day XX performed XX compared QX tests tests per XXXX quarter tests in the and in of last per per of third day quarter

OvaXPlus adding two a fourth back volume. highs we we’ve strong hit from everything performance, few including on we of daily for new incentives. first last to quarter fourth the quarter, We’re weeks And we are each Hurricane Ian, of weeks, impact seen the sales some And drive track. doing can

Looking collaboration to for partner for co-marketing of launch closing outcomes our distribution gap. with for BioReference and this improving at committed mission officially other a our we achievements quarter, and products. equity health OvaXPlus pleased growth shares Laboratories and health women, BioReference is were

optimistic With working potential the of Aspira the both are team sales about and we relationship. for trained together, long-term BioReference this and

gets a weeks as the commercial and on expect fourth started. in product ago, announced, As a quarter, volume few team reminder, we launched previously we the a only impact as small

themselves We are provide optimistic together intend that as grows. and experience our more guidance XXXX to working

including on transfer Finally, technology I relationship Health. an update with want to our our offerings, Women’s genetic provide Axia

than solution genetic attractive is executed screening our our low have to there quality was to when the signed deliver our Axia the agreements, genetics the physician we practices the marketplace it carrier players agreement. disclosed, changed carriers to we Developing before. far seen disruptions in Aspira previously Synergy genetic high has As more and agreement in-house massive tests an dramatically. carrier Since are less industry screening largest screening than was area, Even screening platform. intended available genetics ever

As a our capabilities, the of cease provided agreement. cancellation of result, testing and with to a Axia notice their of development their intent related of notified us us

the yet no in this As quarter. material cancellation platform impact not had financial launched, the had

provide drive of longer our and path carrier differentiated and genetic business, have highest see feel no is and difficult shareholders. resources improve This our will scale. close very it I that small believe made to or a Our cancellation and adoption the genetic strategic the future all away the product caused same and testing took genetic remains as from decision strong, Axia relationship September testing, cancellation XXXX. on will Aspira we directed Axia’s market developing for we the women to we the not offering screening or products the current return business forces business the offering. XX, a has on are impact walk better outcomes our GenetiX been I that Aspira discontinued contract the at will our achieve our do And Synergy. Accordingly, genetics part Synergy of Aspira a an look to effective to it, of of have products with considering

other better be customers, business. focused is launch As and you’ve both are for and including impacted. and adoption remains Synergy the year, for the make opportunities, launch of clear a of We’ve expect We of relationships need come commercial I to clear we have to a beginning we Synergy. eventually OvaWatch, will of heard care, women’s Synergy for that today, continuing labs our the But resulting we including do through envision XXXX critical the thing potential platform. cancer Aspira imminent tools as EndoCheck an much on are and since a Aspira regional women, that with tremendous the OvaXPlus number the changes offering want diagnostic organization. distribution of way EndoCheck. been ovarian and this through expected larger that OvaWatch one Aspira not our We long and

ourselves excellence. all operational position growth, for to we product We’re are success pipeline. me to Ryan on the our believe update on call development innovation With for mean necessary turn taking focused the over and steadfastly that, an are let steps

Ryan Phan

track cancer clinician portfolio that on quarter. we Thank value predictive degree clinical OvaSuite us I toolkit to initial assess to the ovarian in time risk woman our providers ever to woman or focuses journey. with is with of launch will available single clinical help for has that to for requisition test health their for The be with is XX%, of adnexal confidence on with successfully the OvaWatch management our OvaWatch, and OvaWatch, positioned to diagnostic portfolio their adnexal which OvaWatch tools stages adnexal incredibly all cancer assessment on test decision and non-invasive mass. provide a part are next you, risk offer masses announce first masses allowing am Nicole. excited ovarian which with of patients. OvaSuite their patient for a indeterminate Aspira comprehensive OvaXPlus form, of throughout determine appeared appropriate this generation assessment given is higher non-malignant. negative is of

and by launch addressable medical will expressed We our an indeterminate which or earlier of of additional need adnexal proprietary many As or does OvaX with biomarkers, patient surgery. stage, response that OvaWatch OVERA, menopause highest clinician including as may soon probability risk, A clinical present a features, score with with a value. assessment present for assist believe believe potential a to who considering risk woman the favorable clinicians to clinical expansion corresponding the management predictive score providers masses. FDA-cleared X validate risk serum available benign we of monitor. consultation assessment, supporting A algorithm a be a have with OvaWatch, incorporating is our malignancy, that woman score the Nicole manage additional rather population, to indicate and provide patient products, provides an of masses low plan especially Together adnexal status, such indicates OvaWatch. of at and mentioned, the lower in utilizing OvaWatch significant it a not cancer negative represent information unmet a

history, we with include medical their the healthcare management when a tests patient have right clinical expertise, imaging confidently of will to develop time, first the and blood providers, set based For the at studies, them and plan combined allow specialists right time. a that the

said the we plan complete last for peer-reviewed the world submitted for that launch based data publication. intended As market market to I in enrollment product prospective a real At larger substantially be we the manuscript our result total for study our OvaWatch addressable OvaX, for of the support update, OvaXPlus. our of use, expect on than addressable is being to

confident provided to We in sufficient data adoption. right and are and the payer physician clinical will the analytical be study that evaluation

detect Philippines, by The manuscript ethnicity to company the Health. data from continue Environmental population. impact CAXXX. ovarian regardless Notably, of shown test the The cancer, to the menopause research the detecting detection plan was exhibit sensitive OVERA on better cancer. more detecting XX, a stage overall that for this performance accepted CAXXX in we in OVERA including most overall early the arising FDA-cleared publication showed all that to and individual in as had performance addition, and In cancer premenopausal for Research efforts clinical to than which OVERA best to was of in related status such cohort, June research Public of of also ovarian the study stage disease. was In women support compared of early of the be International classifiers, race Journal some show disease posted difficult to and XXXX, our

and in with payer in this States adoption derive that world. study our results expect for the United ongoing study to and Israel, of We along both diverse women provider around products the the

Let’s move endometriosis on to development. our product

to development. to the throughout of reveal have EndoCheck science I I priorities have about first diligence, the phases basis Aspira, the findings the we completed was that great deal for half dataset due pilot our of I planned joined the meaningful endometriosis. support of diagnosis develop of hope In second be assay I of discuss this EndoCheck able supporting [plus our pay] development by to XXXX. regard, path the in forward in of status [ph] launch the a first XXXX collected a of when One and and from learned took various on I understand quarter now to a

agreement and to based Harvard’s multi-omic, & of diagnostic a and generation As we on of previously the for sponsored Cancer non-invasive University announced Institute, circulating with reminder, identify proteins. a Hospital, Medical Women’s endometriosis Brigham Lodz aid microRNAs Farber Dana a

is This efforts meet expected that our the in on collaborators in years goal are a associated laparoscopy older Based group pleased on our primary objective multi-cycle with than study scientists assessment. EndoCheck today, the XXXX. commenced to performance this of clinical to confirm are development scientific endometriosis. also [ph] report compared laparoscopy track clinical XX have and We who we females progress prospective undergo development or to our enrollment endometriosis. observational for to secondary chronic respect with even, study planned with surgical age, to the laparotomy of this But pain of a

We goal golden are statement decreasing the of and enrolling Circling second more actively cash Nicole’s supporting XXXX proud half our share burn, to improving operational of I’m site budget. anticipate back enrollment target that and efficiency reaching launch. study to Aspira

our and made to [ph] of and for discussion sprinted have Bob now We gynecology are help Bob? financial forward have I improvements our performance. progress significant will we growth in goals. turn And Beechey continuing innovation to woman health.

Robert Beechey

XXXX, in of for is period increases increase an of test volume XX, a of $X,XXX,XXX Thank payers AUP XX% increase Product revenue of insurance for XXXX. XXXX, The OvaX XX.X% due was ended you XX, $XX. Ryan. same for the months XX% compared to Medicaid dose volume and revenue percentage in partially product the $X,XXX,XXX and such X to in compared $XX. the higher the increased average volume lower to partially in ended Medicare year, which unit price in $XXX of months by an to an commercial AUP of as to revenue third lower approximately of XXXX prior in product higher Medicaid carriers, the period decreased $XXX a XXXX, an XXXX. offset was same represented quarter quarter also September driven AUP, offset third The of from This compared volume by by the or the X in tests AUP and by performed September AUP.

Medical expenses period primarily decrease as in XX, $XXX,XXX or due by costs access as consulting General in $X,XXX,XXX, XXXX. XXXX, are XXXX number primarily and marketing $XXX compared performed for channel. XX%, expenses profit margin $XXX,XXX research same primarily of and This in XX% XXXX X was costs expenses. XX, the of Compared September with $XXX,XXX & increased for the Institute of related to Our months development for Harvard’s These number of to of related our the Brigham OvaXPlus to validity, period product with same months in provider expenses quarter external or for expenses development XX, the during to $XXX,XXX. product our XX% XXXX XXXX. the The increased personnel for XX, collaboration partially was for or by compared September legal decreased months to to ended administrative OvaWatch result to ended area, tests compared XXXX, X,XXX development offset commercial three XXXX. This a the and performed due XX%. increase the quarter remain second decreases as EndoCheck Cancer clinical for the in XX% and expenses decrease offices same Gross the issuance X% issuance same increased the increased sequentially XXXX, Farber XXXX. to September Research Dana for our XXXX, months of product ended investment to Women’s period by same XX%, quarter months to in and expenses expenses the The and September of period current in ended increases the $X,XXX,XXX months X the increased ended XX, period of University tests flat decreased X,XXX XXXX. XXXX, XXXX. to associated OvaXPlus X compared costs the XXXX. marketing Medicaid was well which to Lodz, by XX%, at X during to involves $XXX was AUP The X ended September and Sales increase in compared compared third increased September XX, tests or the of Hospital, in due to without in warrants period same and for relatively product. the second recruiting marketing increased compared of to

million offering As million of third utilize $X.X September in $XX.X quarter second in public We in to the We operating the during $X.X million the had proceeds XXXX, million in XXXX. during Aspira and investments. quarter compared short-term third million quarter $X.X $X XXXX, third XX, of quarter XXXX, cash activities of net of raised in the XXXX. of and a

the mentioned, severance quarter utilization includes significant investments EndoCheck in cash as Nicole As as well third costs. development,

an per on of XXXX, fail If the May stating previously additional capital we we from for the extend the compliance XX, nasdaq As on period, Aspira compliance or XXXX. until Stock we inclusion would the deadline days, XX, we that to for prior XX Nasdaq disclosed Listing was requirement X, Qualifications minimum June $X to the closing XXXX, be on bid a may received consecutive share deficiency business preceding below for continued common Market, price the November for the market. which Department stock XXX-calendar-day regain eligible letter

I the to for We are will XXX-day the preparing application it back turn now over extension. to submit Nicole.

Nicole Sandford

Thank you, Bob.

for behalf want wish your David? all Board and call thank of to to the questions, endeavors. your I’m contributions to released my take your to that, that I Directors, consulting open now today Executive successor. we moment support of and for onboard let grateful stay transition With for the capacity, us your leaving best the be me in we find you’ll like you the willingness opportunity. Before your for you questions. and another and On us a personally a to take acknowledge future the would company for during help Team in the news to on I

Operator

this At Osborn from you. Cantor with question Our session. Fitzgerald. question-and-answer time, we [Operator conducting Thank Instructions] first is will be Ross a

Ross Osborn

in Hi, future you thought luck endeavors. it’s well. I good working best everyone’s Bob, I morning. your and that, doing of And hope with been nice

Robert Beechey

Thank you, Ross.

Ross Osborn

to at to expected? better what looking a up relative sequential expectations, quarter how Just what below the can do little growth and just So curious growth going quarter were internal the the maybe bit the drive forward? was company we shaped

Nicole Sandford

question. the for Thanks Ross. morning, Good Sure.

year world. our kind in of of adoption OvaXPlus we’re post-COVID So, first of now full

are of the So learning the ordering about patterns pattern, test. we that

through to drive incentives the some number for and the diagnostics, sales in as hit people get We’ve of growth have the additional for quarter to of check-ins strong the deductibles growth a been instituted traditionally of we’re additional – we year. rest what So year. and has their help we will doctors their pull fourth sort doing for that a other with us before which their looking the end think of and quarter,

question. the answers that hopefully So

Ross Osborn

Yes, it and level expect have may this Health Scarlet test, as again I juggling if does. couple would to not, begin a to calls, offering what a them you missed but offering?

Nicole Sandford

hear the the beginning you question. sorry. of I’m I beginning? didn’t repeat the Could

Ross Osborn

just Yes, asking partnership, Scarlet to I about the was they the Health if begin to test? offer

Nicole Sandford

phlebotomy so the Health Yeah, as Scarlet that of overall relationships, was October. in part also the the of so relationship beginning launched BioReference

Ross Osborn

And Okay, great. just clarifying you Thank for then that. last one for me.

Just women’s how I specifically the rollout progressing, of synergies guess, with care?

Nicole Sandford

Sure. is Yeah, as multilayered it rollout we’re care, the of with very talked women’s I’ve pleased sale. a about,

have have to adoption the you and with first, group. the So super physicians to you adopted, the within have platform then still drive

without of to continue the and progress to the But we’re knowledge of successful enhance the So understanding number we test group. drive quite with events them pleased very with that the within far. a physician so

Ross Osborn

great. for Okay, Thanks questions. taking my

Nicole Sandford

Sure. Thank Ross. you,

Operator

next Instructions] Blair. with Andrew is [Operator Brackmann question William from Our

Griffin Soriano

on for for Griffin Thanks questions. This is morning. Andrew. good Hey,

way so you the about $X out burn to of liquidity, one-timers million? about forward the sort $X that mentioned terms that some if closer of right heard the those in Just operational back baseline quarter, burn? think operational in a to million going Is you

Nicole Sandford

one? want you jump on do to that Bob,

Robert Beechey

have continue more the guidance savings expect payback incremental half headcount cost And, execute taken see the a really Yeah, over of we’ve compress of go adoption to on kind for tracks we of into mentioned. of with taken cash – And XXXX. on that our operational our have we’ve activity. time enhances, together top-line flow as we to we the has as vast quarter. made first top-line of for payoff that cash We’ll we but second will we as actions, as see Nicole we actions, year and on as drive utilization and that year reaffirmed that the we initiative obviously, compression the full the the majority reductions marginally

in top-line think, incremental XXXX. more given traction guidance. I of compress And already kind and fourth quarter the cost will terms So, in then of that we’ve significantly change,

Griffin Soriano

Okay…

Nicole Sandford

We’ve sorry, point. and we the costs sales we believe – add not adoption, additional add to oh, similar that, that will that need marketing me bit. significant just we me to past before similar Yeah, OvaWatch to Griffin, let marketing in Thanks that do strategies, Bob. a that for call on little drive to incur let said

we’re sales So, believe going continue to actually, overall and and Bob’s point, sales that within efficiency, marketing. see we spend to to enhanced efficiency

believe So, I compression. do see that we’ll

Griffin Soriano

a few existing expectations just think, on that high then about And the and you. OvaXPlus just got X out OvaWatch, your the TAM maybe with times on expanded ramp, level some revenue thank label there. than Okay, education I is alone larger you’ve

how you’re next driver this OvaWatch, growth a be should meaningful thinking just So about year?

Nicole Sandford

is the rebranded the conversation when Yeah, the that’s We’ve to bifurcating certainly specifically plan. OvaSuite physicians, as between so or that not we’re talk we one other.

as presents the were a manage mass, we is the with to made products already they’ve which a OvaXPlus, them know when about physician treat who for – to talking were as only talking we approved which who clinical where suite very, way of We’re woman for surgically. to and you about only is than different women make very decisions a any decision about

in So with conversation, that decided with woman change often is women behavior, we see masses than see expect will they surgery. be drive it’s to because a will mass it more easier ready will a doctors a a far that different for they’ve very

with So, comprehensive They’re very more been the toolset. early as conversations seeing indications this positive. in providers our have a also

be to OvaWatch plan adoption and of much OVERA the than OvaX would drive So adoption of past. in the certainly faster

Griffin Soriano

code unique most are you and still pricing on likely? Okay. of just And than the a perspective just thinking I more OvaWatch that two CPT OvaX ones quick get if a reimbursements application, is from could crosswalk to

Nicole Sandford

Yes.

Griffin Soriano

that here that then assessment next you’re Phase so still XXXX. of update that than OvaWatch, launch Phase a X on to Phase on X a in Any launching be risk more study? Is one X Phase last will quarter, monitoring. year then And serial Okay. one-time prospective expectations and X this

Nicole Sandford

But plan. Ryan I’d the the study. ask is still to on that’s comment Yeah,

Ryan Phan

XXXX. morning. reason on alter have the ongoing. CRL Yes, Good we study [ph] for Sure. we our is are that the And currently for to still one, plan prospective plan don’t the any for

Griffin Soriano

And of you. luck, best Thank Bob. Great.

Nicole Sandford

Thanks so question. much the for

Operator

of we to like Ladies call and closing question-and-answer Nicole to I remarks. session. end have would back gentlemen, turn the Sandford for the reached the

Nicole Sandford

Thank you, David.

Let third planned usage million quarter, by me reiterating at sustained reaffirming cash focus on execution and our for to during million. wrap up $X.X $X rest our of the the year the

an and OvaWatch, the scaling driving of the through ever including on company of will our With discipline launch The more committed team be adoption energized launch of transform eye Aspira development mission and gynecological the and focused are partners, the portfolio, the provider future of collaboration resources, with allocation the and on laser and payer our is focused of our to achieving OvaSuite health. to imminent accelerating goals EndoCheck. BioReference, towards women’s long-term distribution we than

to in looking forward yet Thank today. and a us our year We’re XXXX you for joining all best XXXX. so to much strong finish

Operator

conference, concludes thank Health, This Aspira today’s participation. you your for Women’s

this You may time. at disconnect lines your

Aspira Women's Health (AWH) 10 Nov 222022 Q3 Earnings call transcript